The Network
“We can not wait for someone else to develop a treatment – we do it ourselves”
What has started as a personal search for two parents has become an international research effort – carried by families, researches and supporters all over the world.
After establishing Cure MCOPS12 in 2020, we built a global network of patient advocates and researchers. We are proud to collaborate with A Cure for Sophia and Friends in the United States and A Cure for Sienna in Australia, united by a shared mission: raise awareness and fundraising to support scientific research and drug development that will ultimately result in a cure for MCOPS12 patients.
Scientific network
We have established a global scientific network with academic institutions (in France and Canada) and a biotech company in the USA to foster fundamental research and develop therapies for MCOPS12.
IGBMC: Institut de génétique et de biologie moléculaire et cellulaire
Dr. Wojciech Krezel, Research Director; Department of Brain Development and Physiology
Centre de recherche Azrieli du CHU Sainte-Justine, Montréal, Canada
Prof. Jacques L. Michaud, MD, FRCP
Director, Centre de recherche Azrieli du CHU Sainte-Justine; Professor of Pediatrics and Neurosciences, Université de Montréal
RareLabs (a division of AlphaRose Therapeutics)
Dr. Rodney A. Bowling Jr
Chief Scientific Officer, RareLabs (A Division of AlphaRose Therapeutics)
Memberships
Further, we a re proud member of the non-profit rare disease alliances Pro Rare Austria and EURORDIS.
